SCHEMBL25920733

SCHEMBL25920733

O=C(Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1)c1ccc2nn[nH]c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR27 Q9NS67 9/20 0.61
KMT2A Q03164 5/20 0.58
MEN1 O00255 4/20 0.58
ALDH1A1 P00352 2/20 0.58
USP2 O75604 1/20 0.58
PKM P14618 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
GRM4 Q14833 1/20 0.52
CYP2C9 P11712 2/20 0.52
CYP2C19 P33261 2/20 0.52
PSMD14 O00487 1/20 0.52
FGB P02675 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
CACNA1B Q00975 1/20 0.52
APBA1 Q02410 1/20 0.52
PLEC Q15149 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
AVPR2 P30518 1/20 0.51
CHEK2 O96017 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25921058 0.91 GPR27 (0.61) GPR27KMT2AMEN1ALDH1A1USP2
SCHEMBL24124854 0.83 POLB (0.65) GPR27KMT2AMEN1ALDH1A1USP2
SCHEMBL25920740 0.80 GPR27 (0.68) GPR27KMT2AMEN1ALDH1A1USP2
SCHEMBL25920226 0.78 GPR27 (0.68) GPR27KMT2AMEN1ALDH1A1USP2
SCHEMBL12010895 0.78 KMT2A (0.83) GPR27KMT2AMEN1ALDH1A1USP2
SCHEMBL27180087 0.77 MEN1 (0.58) GPR27KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL30926420 0.77 MEN1 (0.58) GPR27KMT2AMEN1ALDH1A1SMN1; SMN2
SCHEMBL1247477 0.77 JAK2 (0.58) KMT2AMEN1ALDH1A1USP2SMN1; SMN2
SCHEMBL30926622 0.77 EGFR (0.53) GPR27KMT2AMEN1PKMSMN1; SMN2
SCHEMBL27180430 0.77 EGFR (0.53) GPR27KMT2AMEN1PKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 GPR27 1850/4885KMT2A 578/4885MEN1 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.